Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn’s Disease

Background Infliximab has been shown to have beneficial effects on bone metabolism in patients with Crohn’s disease (CD) although as yet the exact mechanisms have not been fully elucidated. Aim To evaluate the impact of adalimumab therapy on bone metabolism using a combined in vivo and in vitro model. Methods Parathyroid hormone, vitamin D, bone formation markers, bone resorption marker, pro-inflammatory cytokines, anti-inflammatory cytokines, osteoprotegerin, and sRANKL were measured in control patients and pre- and post-treatment with adalimumab in CD patients. The effect of control patients’ and pre- and post-treatment CD patients’ sera on human osteoblasts (hFOB 1.19) in vitro cell viability and differentiation was also analyzed. Results There was a significant increase in bone formation markers osteocalcin ( P